Is Basilea Pharmaceutica AG (BPMUF) a Buy, Sell, or Hold?
OTC : BPMUF
Basilea Pharmaceutica AG
$60.275 USD
$0 (0.0%)
- Volume
- 0
- Average Volume
- 13
- Market Capitalization
- $746M
- P/E Ratio
- 19.77
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $74.00
- Year Low
- $47.50
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.11
Company Overview
OTC
David Veitch
Biotechnology
Healthcare
BPMUF
189
CH
USD
Liquidity Metrics
0.70
5.11
4.68
0.60
0.00
Sales & Valuation
$232.51M
3.59
5.00
13.48
3.94
Profitability
$3.14
$40.22M
17.90%
20.08%
27.95%
11.45%
P/E Metrics
19.77
-0.36
-0.36
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
1.75
8/9
$202.61M
$282.13M
$154.13M
$116.51M
Key Metrics (TTM)
$696.97M
3.86
16.63
5.11
27.95%
14.94%
5.14%
7.55%
$24.99
179 days
Company Executives
| Name | Title |
|---|---|
| Damian Heller | General Counsel & Corporate Secretary |
| David Veitch | Chief Executive Officer |
| Gerrit Hauck | Chief Technology Officer |
| Laurenz Kellenberger | Chief Scientific Officer |
| Marc Engelhardt | Chief Medical Officer |
| Peer Nils Schroder | Head of Corporate Communications & Investor Relations |
| Adesh Kaul | Chief Financial Officer |
| Andreas Kumin | Head of Corporate Development |
| Ursula Eberhardt | Head of Global Human Resources |
| Mark Jones | Head of Global Affairs |
Poll Results
No votes yet today — be the first to share your view!
About Basilea Pharmaceutica AG (OTC:BPMUF) Stock
Basilea Pharmaceutica AG is a biopharmaceutical company already generating revenue from its products, which are designed to fulfill medical needs in the challenging areas of cancer (oncology) and infectious diseases (anti-infectives). The company's product portfolio includes Cresemba, an azole antifungal drug administered intravenously or orally. This medication is approved for treating invasive aspergillosis and mucormycosis in both the United States and the European Union. Additionally, Cresemba is undergoing Phase III clinical trials in Japan for addressing invasive fungal infections. Another key product is Zevtera, an antibiotic prescribed for both community-acquired and hospital-acquired pneumonia. This antibiotic is also advancing through Phase III clinical studies, investigating its ... effectiveness against acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. In its development pipeline, Basilea is advancing Derazantinib, a small molecule inhibitor. This compound is currently in Phase 2 clinical trials for bile duct cancer and in Phase 1/2 trials for bladder and stomach cancers. The company is also developing Lisavanbulin, which acts as a tumor checkpoint controller drug. Founded in the year 2000, Basilea Pharmaceutica AG is based in Basel, Switzerland.
2026-05-28 01:15:00
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea's novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.
Frequently Asked Questions
-
What is the current Basilea Pharmaceutica AG (BPMUF) stock price?
-
Basilea Pharmaceutica AG(OTC:BPMUF) stock price is $60.275 in the last trading session. During the trading session, BPMUF stock reached the peak price of $74 while $47.5 was the lowest point it dropped to. The percentage change in BPMUF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BPMUF stock was $0.
-
BPMUF's industry and sector of operation?
-
The OTC listed BPMUF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BPMUF?
-
Damian Heller | General Counsel & Corporate Secretary
David Veitch | Chief Executive Officer
Gerrit Hauck | Chief Technology Officer
Laurenz Kellenberger | Chief Scientific Officer
Marc Engelhardt | Chief Medical Officer -
How many employees does BPMUF have?
-
Number of BPMUF employees currently stands at 189. BPMUF operates from Hegenheimermattweg 167b, Allschwil, BL 4058, CH.
-
Link for BPMUF official website?
-
Official Website of BPMUF is: https://www.basilea.com
-
How do I contact BPMUF?
-
BPMUF could be contacted at phone #41 61 606 11 11 and can also be accessed through its website. BPMUF operates from Hegenheimermattweg 167b, Allschwil, BL 4058, CH.
-
How many shares of BPMUF are traded daily?
-
The average number of BPMUF shares traded daily for last 3 months was 13.
-
What is the market cap of BPMUF currently?
-
The market value of BPMUF currently stands at $746M with its latest stock price at $60.275